about
Use of a Cumulative Exposure Index to Estimate the Impact of Tap Water Lead Concentration on Blood Lead Levels in 1- to 5-Year-Old Children (Montréal, Canada)Principles of pharmacotherapy: II. PharmacokineticsIntermediate and high grade non Hodgkin's lymphoma in the elderly.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingPhlebotomy treatment for elimination of perfluoroalkyl acids in a highly exposed family: a retrospective case-series.Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.Nanotechnology-Based Approach in Tuberculosis Treatment.Drug treatment of panic disorder.The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices.Association between potentially inappropriate medications from the Beers criteria and the risk of unplanned hospitalization in elderly patients.Drug therapy in dental practice: general principles. Part 1 - Pharmacokinetic considerations.Toxicology screening. How to assure accurate results.Are high-care nursing home residents at greater risk of unplanned hospital admission than other elderly patients when exposed to Beers potentially inappropriate medications?Tailoring Renal Clearance and Tumor Targeting of Ultrasmall Metal Nanoparticles with Particle Density.Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime.Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.Clinical management of anxiety.
P2860
Q28389438-8E5FEFDF-4574-45E2-AF68-F6DC2C09AFDDQ28759539-A24356C8-7AFA-44D5-A2AE-D5CC8D0DD207Q33604350-25898F30-A450-42BF-BF8D-3A8FDE2C7BE9Q34207558-F72CFB16-D2F7-4AB3-90EE-4E9743EAB9C6Q34689412-D9AADD1E-9698-4252-8A56-360EEFB153DFQ35020052-EA985EFC-0DA4-445F-9205-1E8016491C0EQ37624974-36777AA9-1065-4D5F-9F6A-97B11A0AD49BQ37884709-24CC75C8-861F-4D6C-B42D-5BC13104DC7BQ39161825-A9CD556C-BFF2-4CAD-A05E-383F5A86319AQ39278518-D6090163-6BBD-427B-BD11-B77E7B0A34AEQ40259097-DB39C8F7-C99C-4155-B223-9D8B72A6227FQ44541958-B0164FE7-A21F-450C-9926-36992417A044Q45225567-A1B92F63-A71D-4214-8FEF-CF1E93999C09Q47164684-9F899C5A-D2C8-4DB2-842A-EB11E2BC45ADQ47823469-F48A11D4-28AA-47EA-B9AE-D6C17D575479Q51112914-B6ADB90D-77CE-408B-BF87-1212D97D5FD1Q51167834-4F0732EA-881C-42D1-B315-D8D0F1B3F235
P2860
description
1985 nî lūn-bûn
@nan
1985 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Elimination Half-Life of Drugs: Value and Limitations
@ast
Elimination Half-Life of Drugs: Value and Limitations
@en
type
label
Elimination Half-Life of Drugs: Value and Limitations
@ast
Elimination Half-Life of Drugs: Value and Limitations
@en
prefLabel
Elimination Half-Life of Drugs: Value and Limitations
@ast
Elimination Half-Life of Drugs: Value and Limitations
@en
P1476
Elimination Half-Life of Drugs: Value and Limitations
@en
P2093
D J Greenblatt
P304
P356
10.1146/ANNUREV.ME.36.020185.002225
P577
1985-02-01T00:00:00Z